ArticleBreast cancer (Dove Medical Press)2026
SLC2A9-Mediated Uric Acid Homeostasis Modulates Apoptosis in TNBC.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the biological function of SLC2A9 in triple-negative breast cancer (TNBC) and its molecular mechanism of influencing TNBC cells by regulating uric acid (UA) metabolism. Methods: Bioinformatics analysis was performed to screen genes intersecting TNBC and UA metabolism pathways. TNBC cell lines were cultured in vitro, followed by the establishment of SLC2A9 overexpression and knockdown models. Subsequently, the levels of intracellular and extracellular UA were quantified. Cell proliferation, apoptosis, migration, and invasion capabilities were assessed using CCK-8, plate cloning, flow cytometry apoptosis analysis, scratch assay, and Transwell assays. Western blot analysis evaluated the expression of apoptosis-related proteins and UA metabolism proteins. Results: SLC2A9 was significantly downregulated in TNBC tissues and most cell lines. SLC2A9 overexpression inhibited TNBC cell proliferation, migration, and invasion while promoting apoptosis. It also increased extracellular UA secretion and reduced intracellular UA accumulation. Conversely, SLC2A9 knockdown or probenecid treatment reversed these phenotypes. SLC2A9 exerts its effects by upregulating XDH, downregulating ABCG2, and modulating mitochondrial apoptosis pathway protein expression. Conclusion: SLC2A9 regulates the malignant phenotype of TNBC by altering the levels of UA inside and outside the cell. Its anticancer activity depends on UA transport function, making it a promising prognostic biomarker and novel metabolic therapeutic target for TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.